Abstract: An ex vivo method analyzes coagulation function of a subject's blood sample. The method includes providing a whole-blood sample taken from a subject and added with an anti-coagulant substance, treating the blood sample with fluorescent probes, introducing the recalcified blood sample in an analytical device having at least one perfusion chamber, and alternately acquiring at least two series of fluorescence images. The pixels of the acquired images are binarized, followed by generating first and seconds curves of fluorescence intensity vs. time for the formation of the platelet aggregate and of fibrin. Then performing one or more of: generating a first integrated density curve, generating a curve of particle number vs. time, generating a curve of particle size vs. time, generating values of maximum slope and of maximum acceleration, generating values of F/P ratio, generating a lag time value representing the fibrin formation time, and generating area under the curve values.

Abstract: A perfusion device is for evaluating the risk of thrombotic and hemorrhagic diseases linked to blood coagulation processes. In particular, a cartridge is for conducting a dynamic “ex-vivo” evaluation method of the coagulation process in a subjects blood sample, including at least one perfusion chamber, a well for loading the blood sample and reagents, an inclined ascending microchannel connecting the well to a first end of the perfusion chamber and an inclined descending microchannel placed at a second end. Preferably at least one perfusion chamber includes two half-channels of different width, placed in series or in parallel, or the cartridge includes at least two perfusion chambers placed in parallel. At least two of the perfusion chambers have a different width.

Abstract: The present invention relates to a non-viral method for the production of modified mesenchymal stem/stromal cells comprising the use of an additive rich in human-derived platelet growth factors, derived from platelet concentrates, aimed to promote the expansion of said cells. The method further comprises the phase of submitting the cells to electroporation and suspending said mixture in the growth-medium enriched in human-derived platelet growth factors and keeping in incubation. In this way, it is possible to achieve a chemical-physical, non-viral method in compliance with the Good Manufacturing Practice Guidelines (GMP) for advanced cell therapy products, allowing transiently or stably transfect/deliver gene constructs based on electric pulses administration to cells. Said production method is particularly simple and advantageous in terms of productivity and cost-effectiveness, when compared to methods involving viral vectors.

Abstract: Apparatus for analyzing the process of formation of aggregates in a biological fluid, such as blood or hematic fluids, comprising a perfusion chamber provided with at least one micro-channel through which the biological fluid flows, and in which at least one reactive substrate is present, such as a cyto-adhesive substrate, to stimulate the aggregation process in the biological fluid, and impedenziometric detection means associated with the micro-channel, in correspondence to at least one investigation area and disposed, during use, in contact with the flow of biological fluid in transit, in order to detect impedance data of the biological fluid. The impedenziometric detection means comprise at least two first electrodes with an oblong development disposed in the micro-channel, and a plurality of second electrodes with an oblong development disposed in the space comprised between the first electrodes and according to a pattern defining substantially the perimeter of a geometric figure.